User menu

Regorafenib induced severe toxic hepatitis: characterization and discussion.

Bibliographic reference Sacré, Anne ; Lanthier, Nicolas ; Dano, Hélène ; Aydin, Selda ; Leggenhager, Daniela ; et. al. Regorafenib induced severe toxic hepatitis: characterization and discussion.. In: Liver International, Vol. 36, no. 11, p. 1590-1594 (2016)
Permanent URL
  1. Grothey Axel, Cutsem Eric Van, Sobrero Alberto, Siena Salvatore, Falcone Alfredo, Ychou Marc, Humblet Yves, Bouché Olivier, Mineur Laurent, Barone Carlo, Adenis Antoine, Tabernero Josep, Yoshino Takayuki, Lenz Heinz-Josef, Goldberg Richard M, Sargent Daniel J, Cihon Frank, Cupit Lisa, Wagner Andrea, Laurent Dirk, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(12)61900-x
  2. Li Jin, Qin Shukui, Xu Ruihua, Yau Thomas C C, Ma Brigette, Pan Hongming, Xu Jianming, Bai Yuxian, Chi Yihebali, Wang Liwei, Yeh Kun-Huei, Bi Feng, Cheng Ying, Le Anh Tuan, Lin Jen-Kou, Liu Tianshu, Ma Dong, Kappeler Christian, Kalmus Joachim, Kim Tae Won, Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial, 10.1016/s1470-2045(15)70156-7
  3. Iacovelli Roberto, Palazzo Antonella, Procopio Giuseppe, Santoni Matteo, Trenta Patrizia, De Benedetto Angelina, Mezi Silvia, Cortesi Enrico, Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy : TKIs and risk of hepatotoxicity, 10.1111/bcp.12231
  4. Teo Yi Ling, Ho Han Kiat, Chan Alexandre, Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis, 10.1016/j.ctrv.2012.09.004
  5. Strumberg D, Scheulen M E, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K, Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study, 10.1038/bjc.2012.153
  7. Yu K., Geng X., Chen M., Zhang J., Wang B., Ilic K., Tong W., High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury, 10.1124/dmd.113.056267
  8. Lammert Craig, Bjornsson Einar, Niklasson Anna, Chalasani Naga, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, 10.1002/hep.23317
  9. Atkins William M., NON-MICHAELIS-MENTEN KINETICS IN CYTOCHROME P450-CATALYZED REACTIONS, 10.1146/annurev.pharmtox.45.120403.100004
  10. Fernando Harshica, Halpert James R., Davydov Dmitri R., Resolution of Multiple Substrate Binding Sites in Cytochrome P450 3A4:  The Stoichiometry of the Enzyme−Substrate Complexes Probed by FRET and Job's Titration†, 10.1021/bi052491b
  11. Cecchin Erika, Innocenti Federico, D'Andrea Mario, Corona Giuseppe, De Mattia Elena, Biason Paola, Buonadonna Angela, Toffoli Giuseppe, Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan, 10.1200/jco.2008.19.0314
  12. Jiang J, Zhang X, Huo R, Li X, Yang Y, Gai Z, Xu M, Shen L, Cai L, Wan C, Li B, He L, Qin S, Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population, 10.1038/tpj.2014.75
  13. Ramirez J., Liu W., Mirkov S., Desai A. A., Chen P., Das S., Innocenti F., Ratain M. J., Lack of Association between Common Polymorphisms in UGT1A9 and Gene Expression and Activity, 10.1124/dmd.107.015446
  14. Akamine, Anticancer Res, 35, 4037 (2015)
  15. Raissouni Soundouss, Quraishi Zarqa, Al-ghamdi Mohammed, Monzon Jose, Tang Patricia, Vickers Michael M., Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer, 10.1186/s13104-015-1502-4
  16. Kuwayama, Oncol Lett, 11, 85 (2016)